Perrigo Company PLC
PRGO26.740USD
-0.460-1.69%
Cierre 07/07, 16:00（ET）Cotizaciones retrasadas 15 min
3.67BCap. mercado
PérdidaP/E TTM
Más Datos de Perrigo Company PLC Compañía
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
Información de la empresa
Símbolo de cotizaciónPRGO
Nombre de la empresaPerrigo Company PLC
Fecha de salida a bolsaDec 17, 1991
Fundada en2013
Director ejecutivoMr. Patrick Lockwood-Taylor
Número de empleados8379
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 17
DirecciónThe Sharp Building
CiudadDUBLIN
Bolsa de valoresNYSE Consolidated
PaísIreland
Código postalD02 TY74
Teléfono3532696738451
Sitio Webhttps://www.perrigo.com/
Símbolo de cotizaciónPRGO
Fecha de salida a bolsaDec 17, 1991
Fundada en2013
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Patrick Lockwood-Taylor
Mr. Patrick Lockwood-Taylor
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
67.26K
+20.38%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Independent Director
Independent Director
60.29K
+16.75%
Mr. Eduardo Guarita Bezerra
Mr. Eduardo Guarita Bezerra
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
45.95K
+6.36%
Mr. Bradley A. (Brad) Alford
Mr. Bradley A. (Brad) Alford
Independent Director
Independent Director
41.16K
+14.30%
Mr. Robert Willis
Mr. Robert Willis
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
40.45K
+2.51%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
31.84K
+19.30%
Ms. Adriana (Andi) Karaboutis
Ms. Adriana (Andi) Karaboutis
Independent Director
Independent Director
27.63K
+22.91%
Mr. Orlando D. Ashford
Mr. Orlando D. Ashford
Independent Chairman of the Board
Independent Chairman of the Board
22.17K
+40.91%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
10.56K
+95.21%
Ms. Julia M. Brown
Ms. Julia M. Brown
Independent Director
Independent Director
8.03K
+178.57%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Patrick Lockwood-Taylor
Mr. Patrick Lockwood-Taylor
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
67.26K
+20.38%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Independent Director
Independent Director
60.29K
+16.75%
Mr. Eduardo Guarita Bezerra
Mr. Eduardo Guarita Bezerra
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
45.95K
+6.36%
Mr. Bradley A. (Brad) Alford
Mr. Bradley A. (Brad) Alford
Independent Director
Independent Director
41.16K
+14.30%
Mr. Robert Willis
Mr. Robert Willis
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
40.45K
+2.51%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
31.84K
+19.30%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Upper respiratory
211.40M
20.25%
Skincare and personal hygiene
160.10M
15.34%
Healthy lifestyle
137.00M
13.12%
Pain and sleep-aids
130.20M
12.47%
Digestive health
112.60M
10.79%
Other
292.60M
28.03%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
609.30M
58.37%
Europe
412.30M
39.50%
All other countries
22.30M
2.14%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Upper respiratory
211.40M
20.25%
Skincare and personal hygiene
160.10M
15.34%
Healthy lifestyle
137.00M
13.12%
Pain and sleep-aids
130.20M
12.47%
Digestive health
112.60M
10.79%
Other
292.60M
28.03%
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
T. Rowe Price Associates, Inc.
10.39%
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
8.59%
Dimensional Fund Advisors, L.P.
5.19%
State Street Global Advisors (US)
4.88%
Other
60.84%
Accionistas
Accionistas
Proporción
T. Rowe Price Associates, Inc.
10.39%
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
8.59%
Dimensional Fund Advisors, L.P.
5.19%
State Street Global Advisors (US)
4.88%
Other
60.84%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
49.37%
Investment Advisor/Hedge Fund
42.90%
Hedge Fund
6.82%
Research Firm
2.35%
Pension Fund
1.53%
Sovereign Wealth Fund
1.13%
Bank and Trust
0.54%
Individual Investor
0.43%
Venture Capital
0.04%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
777
144.85M
105.36%
-23.47M
2025Q1
812
142.34M
103.61%
-25.15M
2024Q4
806
140.28M
102.80%
-22.73M
2024Q3
798
138.34M
101.41%
-20.68M
2024Q2
800
136.29M
99.93%
-16.34M
2024Q1
799
135.97M
99.77%
-20.56M
2023Q4
809
135.31M
99.86%
-23.17M
2023Q3
797
133.80M
98.82%
-17.47M
2023Q2
837
137.28M
101.45%
-14.92M
2023Q1
857
136.63M
101.13%
-16.53M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Associates, Inc.
14.29M
10.39%
+3.33M
+30.45%
May 31, 2025
The Vanguard Group, Inc.
13.90M
10.11%
-904.53K
-6.11%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
11.81M
8.59%
-158.35K
-1.32%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
7.14M
5.19%
+146.21K
+2.09%
Mar 31, 2025
State Street Global Advisors (US)
6.70M
4.88%
-193.57K
-2.81%
Mar 31, 2025
DePrince, Race & Zollo, Inc.
4.57M
3.32%
+11.29K
+0.25%
Mar 31, 2025
Neuberger Berman, LLC
3.80M
2.76%
+1.00M
+35.79%
Mar 31, 2025
Cooke & Bieler, L.P.
3.54M
2.58%
-33.19K
-0.93%
Mar 31, 2025
Sound Shore Management, Inc.
3.29M
2.39%
+616.39K
+23.10%
Mar 31, 2025
Ion Asset Management Israel Ltd
2.83M
2.06%
+13.89K
+0.49%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
SPDR S&P Pharmaceuticals ETF
3.69%
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
3.27%
Invesco Pharmaceuticals ETF
3.17%
Sound Equity Dividend Income ETF
3.13%
iShares Focused Value Factor ETF
2.6%
ProShares S&P MidCap 400 Dividend Aristocrats ETF
1.97%
iShares U.S. Pharmaceuticals ETF
1.83%
Invesco High Yield Equity Dividend Achievers ETF
1.66%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.62%
Invesco S&P MidCap 400 Pure Value ETF
1.61%
Ver más
SPDR S&P Pharmaceuticals ETF
Proporción3.69%
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
Proporción3.27%
Invesco Pharmaceuticals ETF
Proporción3.17%
Sound Equity Dividend Income ETF
Proporción3.13%
iShares Focused Value Factor ETF
Proporción2.6%
ProShares S&P MidCap 400 Dividend Aristocrats ETF
Proporción1.97%
iShares U.S. Pharmaceuticals ETF
Proporción1.83%
Invesco High Yield Equity Dividend Achievers ETF
Proporción1.66%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.62%
Invesco S&P MidCap 400 Pure Value ETF
Proporción1.61%
Dividendos
Un total de
698.10M
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Feb 19, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Mar 25, 2025 going ex on Mar 07, 2025
Mar 07, 2025
Mar 25, 2025
Mar 07, 2025
Nov 01, 2024
PRGO.NB Final Cash Dividend of gross USD 0.276 paid on Dec 17, 2024 going ex on Nov 29, 2024
Nov 29, 2024
Dec 17, 2024
Nov 29, 2024
Aug 01, 2024
PRGO.NB Interim Cash Dividend of gross USD 0.276 paid on Sep 17, 2024 going ex on Aug 30, 2024
Aug 30, 2024
Sep 17, 2024
Aug 30, 2024
May 01, 2024
PRGO.NB Interim Cash Dividend of gross USD 0.276 paid on Jun 18, 2024 going ex on May 31, 2024
May 31, 2024
Jun 18, 2024
May 31, 2024
Feb 26, 2024
PRGO.NB Interim Cash Dividend of gross USD 1.1 paid on Mar 26, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Mar 26, 2024
Mar 07, 2024
Nov 03, 2023
PRGO.NB Final Cash Dividend of gross USD 0.273 paid on Dec 19, 2023 going ex on Nov 30, 2023
Dec 01, 2023
Dec 19, 2023
Nov 30, 2023
Aug 02, 2023
PRGO.NB Interim Cash Dividend of gross USD 0.273 paid on Sep 19, 2023 going ex on Aug 31, 2023
Sep 01, 2023
Sep 19, 2023
Aug 31, 2023
May 04, 2023
PRGO.NB Interim Cash Dividend of gross USD 0.273 paid on Jun 20, 2023 going ex on Jun 01, 2023
Jun 02, 2023
Jun 20, 2023
Jun 01, 2023
Feb 21, 2023
PRGO.NB Interim Cash Dividend of gross USD 0.273 paid on Mar 28, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 28, 2023
Mar 09, 2023
Nov 04, 2022
PRGO.NB Final Cash Dividend of gross USD 0.26 paid on Dec 20, 2022 going ex on Dec 01, 2022
Dec 02, 2022
Dec 20, 2022
Dec 01, 2022
Ver más
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
